Tag Archives: pharmaceutical

Drug pricing bill faces uphill climb in an impeachment-focused Congress

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

With the news out of Washington coming at us fast and furiously, it may have been easy to miss the introduction of House Speaker Nancy Pelosi’s new proposal to curb the cost of prescription drugs.

Drug pricing is an especially important issue for older adults, many of whom are on multiple medications and take more prescription drugs on average than any other age group in the United States, according to the American Geriatrics Society.

Continue reading

Panel to look at challenges of fighting superbugs

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

Since antibiotics were widely introduced in the mid 1940’s, scientists warned of microbes’ innate ability to evolve and develop resistance. People were cautioned to be judicious with antimicrobials, because overuse could breed “superbugs,” germs resistant to most or all antibiotics.

Indeed, microbes have developed resistance to virtually every new class of antibiotics introduced. Up until the 1980s, however, most pharmaceutical companies kept developing new antibiotics. When a drug developed resistance, there was a new one in the development pipeline that could take its place. Continue reading

2019 AHCJ Reporting Fellows on Health Care Performance named

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates AHCJ's social media efforts and edits and manages production of association guides, programs and newsletters.

The Association of Health Care Journalists has awarded AHCJ Reporting Fellowships on Health Care Performance to four journalists who intend to pursue significant projects in 2019. The program, in its ninth year, is meant to help journalists understand and report on the performance of local health care markets and the U.S. health system as a whole.

The fellowship program, supported by The Commonwealth Fund, is intended to give experienced print, broadcast and online reporters an opportunity to concentrate on the performance of health care systems – or significant parts of those systems – locally, regionally or nationally. The fellows are able to examine policies, practices and outcomes, as well as the roles of various stakeholders.

Continue reading 

Former CMS leader discusses vulnerable populations, drug pricing and a health journalist he admires

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Donald Berwick

Don Berwick is a former administrator of the Centers for Medicare and Medicaid Services (CMS) under President Obama. Berwick’s long résumé includes leadership positions at the U.S. Preventive Services Task Force, the National Advisory Council of the Agency for Healthcare Research and Quality, the Institute of Medicine’s Governing Council, the IOM’s Global Health Board, and on President Clinton’s Advisory Commission on Consumer Protection and Quality in the Healthcare Industry. He is president emeritus of the Institute for Healthcare Improvement. He also teaches at Harvard Medical School and is on staff at several major Massachusetts hospitals.

Prior to his keynote address on social determinants of health at the recent Institute for Healthcare Improvement conference in Orlando, Fla., Berwick sat with me to talk about some of today’s most pressing health care issues. [This interview has been edited for clarity and length.] Continue reading

CVS-Aetna merger approval raises questions about competition and drug costs

Joseph Burns

About Joseph Burns

Joseph Burns (@jburns18), a Massachusetts-based independent journalist, is AHCJ’s topic leader on health insurance. He welcomes questions and suggestions on insurance resources and tip sheets at joseph@healthjournalism.org.

Photo: afagen via Flickr

The merger of CVS Health, one of the nation’s largest pharmacy retailers, with third-largest health insurer Aetna has the potential to transform the health care system and raises concerns about the effect the merger could have on drug prices and competition. This would be the first time that a large pharmacy retailer gains control of one of the nation’s largest health insurers. CVS Health not only has 9,800 retail outlets in nearly every state (except Wyoming), but also 94 million members in pharmacy benefit manager CVS/Caremark. Continue reading

New investment hopes to spur cure for dementia

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Liz SeegertActress Jane Krakowski, talking to Katie Couric, teared up as she spoke about her dad’s diagnosis of early onset dementia at age 61.

Alzheimer’s disease is the sixth leading cause of death in the U.S. Despite decades of research, there’s still no cure, and few options to slow or minimize symptoms. The last Alzheimer’s drug was approved more than 15 years ago, but a new campaign, called Disrupting Dementia, hopes to drive new diagnostics and treatments while also supporting patients and families affected by this devastating condition.

Continue reading